Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06585527 | Clinical Study on the Safety and Efficacy of TS-2021 in the Treatment of Recurrent Malignant Glioma | unknown | Phase 1 | 30 | Beijing Neurosurgical InstituteOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT06279767 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05868083 | The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma | unknown | Phase 1 | 16 | Shanghai Simnova Biotechnology Co.,Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT03582514 | PreOperative Brain Irradiation in Glioblastoma(POBIG) | unknown | Phase 1 | 18 | The Christie NHS Foundation TrustOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04156347 | Topotecan Episcleral Plaque for Treatment of Retinoblastoma | unknown | Phase 1 | 42 | Targeted Therapy Technologies, LLCINDUSTRY | 1 | Oct 31, 2023 | clinicaltrials |
| NCT04967690 | A Dose Escalation Study to Estimate MTD, DLTs and Pharmacokinetics After a Single Intracranial Dose of SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed GBM(TARGLIO) | unknown | Phase 1 | 27 | Double Bond Pharmaceutical ABINDUSTRY | 0 | Jul 6, 2023 | clinicaltrials |
| NCT05929456 | Multispectral Bimodal Fluorescence Guided Surgery of High-grade Glioma With Cetuximab-800CW and 5-ALA (5-aminolevulinic Acid)(MIRROR) | unknown | Phase 1 | 21 | University Medical Center GroningenOTHER | 1 | Jul 3, 2023 | clinicaltrials |
| NCT05363826 | Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac® | unknown | Phase 1 | 30 | Photolitec LLCINDUSTRY | 1 | Apr 13, 2023 | clinicaltrials |
| NCT01672463 | Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients(OKN-007) | unknown | Phase 1 | 31 | Oblato, Inc.INDUSTRY | 1 | Mar 29, 2023 | clinicaltrials |
| NCT05782959 | Phase 1 Study of BCD-245 in Subjects With Neuroblastoma | unknown | Phase 1 | 24 | BiocadINDUSTRY | 1 | Mar 24, 2023 | clinicaltrials |
| NCT05737368 | Treatment of Recurrent Glioblastoma With Fractionated Radiotherapy Combined With Cadonilimab | unknown | Phase 1 | 11 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 0 | Feb 21, 2023 | clinicaltrials |
| NCT04642937 | Study of CD200 Activation Receptor Ligand (CD200AR-L) and Allogeneic Tumor Lysate Vaccine Immunotherapy for Recurrent Glioblastoma | unknown | Phase 1 | 24 | OX2 TherapeuticsINDUSTRY | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05700955 | Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 30 | University of LouisvilleOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05540873 | A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) | unknown | Phase 1 | 18 | CellabMEDINDUSTRY | 1 | Jan 6, 2023 | clinicaltrials |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | unknown | Phase 1 / Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT04385173 | Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma | unknown | Phase 1 | 12 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05663125 | LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas | unknown | Phase 1 / Phase 2 | 10 | Beijing Tiantan HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT05135858 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma(METHOGLU) | unknown | Phase 1 | 18 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05095441 | A Clinical Study of Intratumoral MVR-C5252 (C5252) in Patients With Recurrent or Progressive Glioblastoma | unknown | Phase 1 | 51 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT03722342 | TTAC-0001 and Pembrolizumab Combination phase1b Trial in Recurrent Glioblastoma | unknown | Phase 1 | 9 | PharmAbcineINDUSTRY | 1 | Aug 17, 2022 | clinicaltrials |
| NCT02285959 | Super-Selective Intraarterial Intracranial Infusion of Bevacizumab (Avastin) for Glioblastoma Multiforme | unknown | Phase 1 | 30 | Global Neurosciences InstituteOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT02013336 | Phase 1 Dose-escalating Study of MM-398 (Irinotecan Sucrosofate Liposome Injection) Plus Intravenous Cyclophosphamide in Recurrent or Refractory Pediatric Solid Tumors | unknown | Phase 1 | 30 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
| NCT05201326 | Irinotecan And Bevacizumab Combined With Re-radiotherapy in Recurrent Glioblastoma | unknown | Phase 1 | 20 | Ruijin HospitalOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05131763 | NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors | unknown | Phase 1 | 3 | Fudan UniversityOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05108012 | Nk Cell Therapy for Recurrent Glioblastoma Multiform Patients | unknown | Phase 1 | 5 | Royan InstituteOTHER_GOV | 1 | Nov 22, 2021 | clinicaltrials |
| NCT00983398 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | unknown | Phase 1 / Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 81 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05021770 | Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma | unknown | Phase 1 / Phase 2 | 29 | Huiqiang HuangOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04943718 | Personalized Vaccine for Patients With Recurrent Malignant Glioma | unknown | Phase 1 | 10 | Xuanwu Hospital, BeijingOTHER | 1 | Jun 29, 2021 | clinicaltrials |
| NCT04772846 | Chloroquine for Glioblastoma. | unknown | Phase 1 / Phase 2 | 60 | Egyptian Medical SyndicateOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03463733 | Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)(HUTMZ) | unknown | Phase 1 | 54 | M.E. van LindeOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04547621 | HSRT and IMRT Chemoradiotherapy for Newly Diagnosed GBM(HSCK-010) | unknown | Phase 1 / Phase 2 | 50 | Huashan HospitalOTHER | 1 | Sep 14, 2020 | clinicaltrials |
| NCT03734913 | A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors | unknown | Phase 1 | 65 | Guangdong Zhongsheng Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 22, 2020 | clinicaltrials |
| NCT01701479 | Long Term Continuous Infusion ch14.18/CHO Plus s.c. Aldesleukin (IL-2)(LTI) | unknown | Phase 1 / Phase 2 | 288 | St. Anna KinderkrebsforschungOTHER | 7 | Jul 14, 2020 | clinicaltrials |
| NCT03231501 | HMPL-813 in Treating Patients With Glioblastoma | unknown | Phase 1 | 29 | Hutchison Medipharma LimitedINDUSTRY | 1 | Jun 16, 2020 | clinicaltrials |
| NCT04388033 | Clinical Study of an Dendritic and Glioma Cells Fusion Vaccine With IL-12 for Treatment-naïve GBM Patients. | unknown | Phase 1 / Phase 2 | 10 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jun 9, 2020 | clinicaltrials |
| NCT04120350 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty(REMLA) | unknown | Phase 1 / Phase 2 | 47 | Peking Union Medical College HospitalOTHER | 1 | Jun 5, 2020 | clinicaltrials |
| NCT03392545 | Combination of Immunization and Radiotherapy for Malignant Gliomas (InSituVac1)(InSituVac1) | unknown | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | Jul 11, 2019 | clinicaltrials |
| NCT04004975 | Clinical Study on the Treatment of Recurrent Glioblastoma With Anlotinib | unknown | Phase 1 / Phase 2 | 50 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jul 2, 2019 | clinicaltrials |
| NCT03687034 | A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma | unknown | Phase 1 | 21 | Leaf Vertical Inc.INDUSTRY | 0 | Feb 26, 2019 | clinicaltrials |
| NCT02173093 | Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma | unknown | Phase 1 / Phase 2 | 40 | University of VirginiaOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT03631836 | Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma(MARELLE01) | unknown | Phase 1 | 34 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Oct 31, 2024source: clinicaltrials